Centessa Pharmaceuticals anuncia datos preliminares positivos del estudio preliminar de eficacia de SerpinPC en pacientes con hemofilia A y B grave que no están recibiendo tratamiento de profilaxis
September 13, 2021 09:51 ET
|
Centessa Pharmaceuticals plc
~ 88 % de reducción en la mediana de la tasa anualizada de hemorragia (TAH) para todas las hemorragias y 94 % de reducción en la mediana de TAH para las hemorragias articulares espontáneas en la dosis...
Centessa Pharmaceuticals annuncia dati topline positivi da uno studio “proof of concept” di SerpinPC in pazienti affetti da grave emofilia A e B non in profilassi
September 13, 2021 09:51 ET
|
Centessa Pharmaceuticals plc
~ Riduzione dell’88% del tasso di sanguinamento annualizzato (ABR) mediano per tutti gli emorragie e riduzione del 94% dell'ABR mediano per emorragie articolari spontanee nella dose più elevata...
Centessa Pharmaceuticals gibt positive Topline-Daten aus der Proof-of-Concept-Studie zu SerpinPC bei Patienten mit schwerer Hämophilie A und B ohne prophylaktische Behandlung bekannt
September 13, 2021 09:51 ET
|
Centessa Pharmaceuticals plc
~ 88 % Reduktion der medianen annualisierten Blutungsrate (Annualized Bleeding Rate, ABR) bei allen Blutungen und 94 % Reduktion der medianen ABR bei spontanen Gelenkeinblutungen bei der höchsten...
Centessa Pharmaceuticals Announces Positive Topline Data from Proof-of-Concept Study of SerpinPC in Severe Hemophilia A and B Patients Not on Prophylaxis
September 09, 2021 07:30 ET
|
Centessa Pharmaceuticals plc
~ 88% reduction in median Annualized Bleeding Rate (ABR) for all bleeds and 94% reduction in median ABR for spontaneous joint bleeds in highest dose tested ~ ~ SerpinPC observed to be well-tolerated...
Centessa Pharmaceuticals participará en la 19.ª edición de la Morgan Stanley Annual Global Healthcare Conference que se celebrará de forma virtual
September 02, 2021 14:20 ET
|
Centessa Pharmaceuticals plc
CAMBRIDGE, Massachusetts y LONDRES, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) ha anunciado hoy que el doctor en medicina Saurabh Saha, director ejecutivo de la...
Centessa Pharmaceuticals примет участие в презентации на 19-й виртуальной конференции Morgan Stanley Virtual Global Healthcare
September 02, 2021 14:20 ET
|
Centessa Pharmaceuticals plc
КЕМБРИДЖ, Массачусетс, ЛОНДОН, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) объявила сегодня, что Saurabh Saha, доктор медицины, доктор философии, главный...
Centessa Pharmaceuticals annuncia la partecipazione alla XIX edizione della Global Healthcare Conference annuale virtuale di Morgan Stanley
September 02, 2021 14:20 ET
|
Centessa Pharmaceuticals plc
CAMBRIDGE, Mass. e LONDRA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) ha annunciato oggi la partecipazione di Saurabh Saha, M.D., Ph.D e Chief Executive Officer,...
Centessa Pharmaceuticals nimmt an der virtuellen Konferenz Morgan Stanley 19th Annual Global Healthcare Conference teil
September 02, 2021 14:20 ET
|
Centessa Pharmaceuticals plc
CAMBRIDGE, Mass. und LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) gab heute bekannt, dass Saurabh Saha, M.D., Ph.D., Chief Executive Officer, am Dienstag,...
Centessa Pharmaceuticals fera une présentation lors de la 19e conférence mondiale annuelle virtuelle Morgan Stanley sur les soins de santé
September 02, 2021 14:20 ET
|
Centessa Pharmaceuticals plc
CAMBRIDGE, Massachusetts & LONDRES, 02 sept. 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq : CNTA) a annoncé aujourd'hui que Saurabh Saha, M.D., Ph.D., président-directeur...
Centessa Pharmaceuticals aanwezig op virtuele 19e jaarlijkse Global Healthcare Conference van Morgan Stanley
September 02, 2021 14:20 ET
|
Centessa Pharmaceuticals plc
CAMBRIDGE, Massachusetts en LONDEN, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) kondigde vandaag aan dat Saurabh Saha, M.D., Ph.D., Chief Executive Officer, zal...